[go: up one dir, main page]

NO20041814L - Fremgangsmate for a behandle hepatitt virusinfeksjoner med en mulitfaseinterferonavleveringsprofil - Google Patents

Fremgangsmate for a behandle hepatitt virusinfeksjoner med en mulitfaseinterferonavleveringsprofil

Info

Publication number
NO20041814L
NO20041814L NO20041814A NO20041814A NO20041814L NO 20041814 L NO20041814 L NO 20041814L NO 20041814 A NO20041814 A NO 20041814A NO 20041814 A NO20041814 A NO 20041814A NO 20041814 L NO20041814 L NO 20041814L
Authority
NO
Norway
Prior art keywords
procedure
phase
hepatitis virus
virus infections
delivery profile
Prior art date
Application number
NO20041814A
Other languages
English (en)
Inventor
Peter Van Vlasselaer
Gary Visor
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of NO20041814L publication Critical patent/NO20041814L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20041814A 2001-10-05 2004-05-04 Fremgangsmate for a behandle hepatitt virusinfeksjoner med en mulitfaseinterferonavleveringsprofil NO20041814L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32774401P 2001-10-05 2001-10-05
PCT/US2002/030837 WO2003030923A1 (en) 2001-10-05 2002-09-26 Method of treating hepatitis virus infection with a multiphasic interferon delivery profile

Publications (1)

Publication Number Publication Date
NO20041814L true NO20041814L (no) 2004-06-11

Family

ID=23277854

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041814A NO20041814L (no) 2001-10-05 2004-05-04 Fremgangsmate for a behandle hepatitt virusinfeksjoner med en mulitfaseinterferonavleveringsprofil

Country Status (15)

Country Link
US (2) US20050063949A1 (no)
EP (1) EP1450838A4 (no)
JP (1) JP2005508943A (no)
KR (1) KR20050030886A (no)
CN (1) CN1738635A (no)
AR (1) AR036728A1 (no)
BR (1) BR0213103A (no)
CA (1) CA2460690A1 (no)
HU (1) HUP0401818A2 (no)
IL (1) IL160965A0 (no)
MX (1) MXPA04003238A (no)
NO (1) NO20041814L (no)
PL (1) PL369870A1 (no)
WO (1) WO2003030923A1 (no)
ZA (1) ZA200402236B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2587002A (en) 2000-11-03 2002-05-15 Biomedicines Inc Method for short-term and long-term drug dosimetry
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1561470A1 (en) * 2003-06-20 2005-08-10 Innogenetics N.V. HCV vaccines comprising the envelope-1 (E1) protein or the corresponding DNA and at least one antiviral agent
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
CN101453982B (zh) 2006-05-30 2011-05-04 精达制药公司 两件式内部通道渗透递送系统流动调节器
NZ593017A (en) 2006-08-09 2011-08-26 Intarcia Therapeutics Inc Piston assembly for positioning lumen in an osmotic delivery system having groove to retain elastomeric O-ring
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
CN101801405A (zh) 2007-08-07 2010-08-11 先进科技及再生医学有限责任公司 包含于酸性水溶液中的gdf-5的蛋白质配方
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US20090246171A1 (en) * 2008-03-27 2009-10-01 Van Antwerp William P Automatic system for dose control in treating hepatitis c using infusion pumps
WO2009120991A2 (en) * 2008-03-27 2009-10-01 Medtronic, Inc. Pharmacokinetic and pharmacodynamic tools to define patient specific therapeutic regimens
CN102026619A (zh) 2008-04-14 2011-04-20 先进科技及再生医学有限责任公司 液体缓冲的gdf-5制剂
US9561214B2 (en) * 2008-10-16 2017-02-07 Array Biopharma Inc. Method of treatment using inhibitors of mitosis
US20110027229A1 (en) * 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
SMT201700583T1 (it) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
CN102711871A (zh) 2010-06-16 2012-10-03 麦德托尼克公司 用于稳定药物递送装置中的药物的阻尼系统
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SG2014011647A (en) 2011-10-21 2014-08-28 Abbvie Inc Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon.
CN103071147A (zh) * 2011-10-26 2013-05-01 麦德托尼克公司 干扰素-α向乙型肝炎感染的患者的连续皮下施用
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
JP6993235B2 (ja) 2015-06-03 2022-01-13 インターシア セラピューティクス，インコーポレイティド インプラントの設置及び撤去システム
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
EP3733694A1 (en) 2016-05-16 2020-11-04 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5980884A (en) * 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6455051B1 (en) * 1997-10-13 2002-09-24 Otsuka Pharmaceutical Co., Ltd. Ameliorant for hepatitis C therapeutic effect and application thereof
US6824768B2 (en) * 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
US6245740B1 (en) * 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
AU2587002A (en) * 2000-11-03 2002-05-15 Biomedicines Inc Method for short-term and long-term drug dosimetry

Also Published As

Publication number Publication date
BR0213103A (pt) 2004-09-21
HUP0401818A2 (hu) 2004-11-29
MXPA04003238A (es) 2004-07-08
ZA200402236B (en) 2005-03-22
EP1450838A4 (en) 2005-09-28
AR036728A1 (es) 2004-09-29
KR20050030886A (ko) 2005-03-31
PL369870A1 (en) 2005-05-02
US20090196853A1 (en) 2009-08-06
US20050063949A1 (en) 2005-03-24
WO2003030923A1 (en) 2003-04-17
IL160965A0 (en) 2004-08-31
EP1450838A1 (en) 2004-09-01
JP2005508943A (ja) 2005-04-07
CA2460690A1 (en) 2003-04-17
CN1738635A (zh) 2006-02-22

Similar Documents

Publication Publication Date Title
NO20041814L (no) Fremgangsmate for a behandle hepatitt virusinfeksjoner med en mulitfaseinterferonavleveringsprofil
ATE382605T1 (de) Hepatitis c virus polymerase inhibitoren mit heterobicylischer struktur
IS7530A (is) Lifrarbólgu C-veirutálmar
IL164729A0 (en) Nucleoside derivatives for treating hepatitis c virus infection
PL376043A1 (en) Nucleoside derivatives for treating hepatitis c virus infection
DE60139127D1 (de) Von hepatitis c virus
IS8476A (is) Lifrarbólgu C-veirutálmar
IS8475A (is) Lifrarbólgu C-veirutálmar
DK1351981T3 (da) Et virus, der forårsager luftvejssygdom hos modtagelige pattedyr
DK3210637T3 (da) Infusionssæt
DK1383560T4 (da) Infusionssæt
DE50206101D1 (de) Induktives bauteil
IL157251A0 (en) Hepatitis b virus treatment
NO20030239D0 (no) Modifisert virus
IL158428A0 (en) Vaccine composition comprising at least one hiv virus antigen
IL162236A0 (en) Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use
DE60238924D1 (de) Abwälzfräser
AU2003294757A8 (en) Formulations useful against hepatitis c virus infections
DE60201193D1 (de) Induktives Bauteil
DK1220858T3 (da) Oxazinoquinoloner der er anvendelige til behandling af virale infektioner
EE200200693A (et) Interferoon hulgiskleroosi raviks
EP1437408A4 (en) NOVEL ANTISENSE OLIGONUCLEOTIDE DERIVATIVES AGAINST HEPATITIS C VIRUS
DK1180041T3 (da) Vaccine med ISA-virus
EP1370283A4 (en) PREVENTION OF RECURRENT VIRAL DISEASES
NO20041815L (no) Fremgangsmater for a behandle leverfibrose og hepatitt C-virusinfeksjon

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application